Systemic chemotherapy in metastatic TNBC polarizes effector T cell differentiation.

IF 6 2区医学 Q1 ONCOLOGY

Cancer Cell International Pub Date : 2025-10-22 DOI:10.1186/s12935-025-04011-6

Hye-Yeon Ju, Hyundong Yoon, Seungpil Jung, Serk In Park, Tae Kon Kim, Mi-Ryung Han

{"title":"Systemic chemotherapy in metastatic TNBC polarizes effector T cell differentiation.","authors":"Hye-Yeon Ju, Hyundong Yoon, Seungpil Jung, Serk In Park, Tae Kon Kim, Mi-Ryung Han","doi":"10.1186/s12935-025-04011-6","DOIUrl":null,"url":null,"abstract":"Background: Triple-negative breast cancer (TNBC) has the poorest prognosis among the three major subtypes of breast cancer, and more than one-third of patients with TNBC experience recurrence or distant metastasis. Despite advances in diverse immunotherapy strategies for metastatic TNBC (mTNBC), multiple mechanisms underlying resistance to treatment remain unknown.Methods: In this study, the dynamic changes in the immune landscape in mTNBC were assessed and compared with healthy donors using single-cell RNA sequencing (scRNA-seq) analysis. By integrating internal and public scRNA-seq data, 61,149 cells extracted from East Asian patients with mTNBC and 51,448 cells extracted from East Asian healthy donors were used to landscape a comprehensive cellular profile of mTNBC.Results: Results showed that nine overexpressed genes from patients with mTNBC in effector T cells such as CTSW, PRF1, GNLY, GZMA, CCL5, KLRD1, KLRB1, B2M, and GZMB exhibited favorable survival prognoses. In addition, effector T cells enriched in patients with mTNBC were more differentiated compared with those enriched in healthy donors.Conclusion: Collectively, this study is the first to provide potential diagnostic and therapeutic targets of East Asian chemotherapy-treated mTNBC with regard to effector T cells.","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"371"},"PeriodicalIF":6.0000,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-04011-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Triple-negative breast cancer (TNBC) has the poorest prognosis among the three major subtypes of breast cancer, and more than one-third of patients with TNBC experience recurrence or distant metastasis. Despite advances in diverse immunotherapy strategies for metastatic TNBC (mTNBC), multiple mechanisms underlying resistance to treatment remain unknown.

Methods: In this study, the dynamic changes in the immune landscape in mTNBC were assessed and compared with healthy donors using single-cell RNA sequencing (scRNA-seq) analysis. By integrating internal and public scRNA-seq data, 61,149 cells extracted from East Asian patients with mTNBC and 51,448 cells extracted from East Asian healthy donors were used to landscape a comprehensive cellular profile of mTNBC.

Results: Results showed that nine overexpressed genes from patients with mTNBC in effector T cells such as CTSW, PRF1, GNLY, GZMA, CCL5, KLRD1, KLRB1, B2M, and GZMB exhibited favorable survival prognoses. In addition, effector T cells enriched in patients with mTNBC were more differentiated compared with those enriched in healthy donors.

Conclusion: Collectively, this study is the first to provide potential diagnostic and therapeutic targets of East Asian chemotherapy-treated mTNBC with regard to effector T cells.

查看原文本刊更多论文

转移性TNBC的全身化疗使效应T细胞分化极化。

背景：三阴性乳腺癌（triple negative breast cancer， TNBC）是乳腺癌三大亚型中预后最差的，三分之一以上的TNBC患者出现复发或远处转移。尽管转移性TNBC （mTNBC）的多种免疫治疗策略取得了进展，但对治疗耐药的多种机制仍不清楚。方法：本研究采用单细胞RNA测序（scRNA-seq）分析方法，评估mTNBC患者免疫景观的动态变化，并与健康供者进行比较。通过整合内部和公开的scRNA-seq数据，从东亚mTNBC患者中提取的61149个细胞和从东亚健康供体中提取的51448个细胞被用于绘制mTNBC的全面细胞图谱。结果：mTNBC患者效应T细胞中的9个过表达基因CTSW、PRF1、GNLY、GZMA、CCL5、KLRD1、KLRB1、B2M和GZMB表现出良好的生存预后。此外，mTNBC患者体内富集的效应T细胞比健康供者体内富集的效应T细胞分化程度更高。结论：总的来说，本研究首次提供了东亚化疗治疗的mTNBC在效应T细胞方面的潜在诊断和治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.